A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria

Trial Profile

A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate mofetil; Mycophenolic acid; Tacrolimus
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Feb 2016 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018 as per ClinicalTrials.gov record.
    • 11 Feb 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2018 as per ClinicalTrials.gov record.
    • 07 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top